deguelin has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Hu, X; Liu, W; Peng, L; Yang, F; Yi, H | 1 |
| Feng, B; Mu, J; Qi, W; Tang, JY; Wei, Y; Wu, Q; Yang, LL; Zeng, W; Zhang, Q | 1 |
2 other study(ies) available for deguelin and Alloxan Diabetes
| Article | Year |
|---|---|
The Natural Rotenoid Deguelin Ameliorates Diabetic Neuropathy by Decreasing Oxidative Stress and Plasma Glucose Levels in Rats via the Nrf2 Signalling Pathway.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Hypoglycemic Agents; Male; NF-E2-Related Factor 2; Oxidative Stress; Rats, Sprague-Dawley; Rotenone; Signal Transduction | 2018 |
MG132 protects against renal dysfunction by regulating Akt-mediated inflammation in diabetic nephropathy.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Glomerular Mesangium; Glucose; Humans; Inflammation; Inflammation Mediators; Kidney; Leupeptins; Male; Mesangial Cells; Proteasome Inhibitors; Protective Agents; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rotenone; Signal Transduction | 2019 |